{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:30:34Z","timestamp":1761625834290,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.dld.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T16:30:41Z","timestamp":1683131441000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting"],"prefix":"10.1016","volume":"56","author":[{"given":"Luca","family":"Degli Esposti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-490X","authenticated-orcid":false,"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Sangiorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Saragoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Dovizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.dld.2023.04.022_bib0001","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10114","key":"10.1016\/j.dld.2023.04.022_bib0004","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.04.022_bib0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/00365521.2015.1014407","article-title":"The epidemiology of inflammatory bowel disease","volume":"50","author":"Burisch","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2023.04.022_bib0006","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with ulcerative colitis: past, present, and future","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00019053-200220100-00001","article-title":"Cost of illness of Crohn's disease","volume":"20","author":"Bodger","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.dld.2023.04.022_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2036.1999.00437.x","article-title":"Clinical economics review: medical management of inflammatory bowel disease","volume":"13","author":"Ward","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dld.2023.04.022_bib0009","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2023.01.155","article-title":"Italian group for the study of inflammatory bowel disease (IG-IBD); working panel; review panel. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology","author":"Macaluso","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","volume":"43","author":"Orlando","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2023.04.022_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.dld.2023.04.022_bib0014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5217\/ir.2022.00117","article-title":"Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education","volume":"20","author":"Kim","year":"2022","journal-title":"Intest Res"},{"issue":"5","key":"10.1016\/j.dld.2023.04.022_bib0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4240\/wjgs.v8.i5.363","article-title":"Infammatory bowel disease surgery in the biologic era","volume":"8","author":"Ferrari","year":"2016","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.dld.2023.04.022_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2023.04.022_bib0017","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for infammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.dld.2023.04.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)62379-3","article-title":"Treatment patterns, complications, and disease relapse in a real-world population of moderate-to-severe ulcerative colitis patients initiating immunosuppressive therapy","volume":"144","author":"Davis","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.dld.2023.04.022_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"54","author":"Bots","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2023.04.022_bib0021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn's disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2023.04.022_bib0022","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.04.022_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","article-title":"Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study","volume":"Suppl 1","author":"Jahnsen","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2023.04.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.04.022_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.01.035","article-title":"Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease: a population-based analysis","volume":"15","author":"Targownik","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.04.022_bib0027","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn's disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.dld.2023.04.022_bib0028","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res"},{"issue":"9","key":"10.1016\/j.dld.2023.04.022_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2023.04.022_bib0031","first-page":"147","article-title":"Patients Perception of Risks and Benefits of Biologic Therapy","volume":"26","author":"De Felice","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0032","first-page":"izac271","article-title":"German inflammatory bowel diseases study group (GISG). Real-world comparative effectiveness of ustekinumab vs Anti-TNF in Crohn's disease with propensity score adjustment: induction phase results from the prospective, observational RUN-CD study","author":"Bokemeyer","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0033","first-page":"izac269","article-title":"Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in taiwan: a prospective nationwide registry (VIOLET) study","author":"Lin","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221130554","article-title":"Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: a retrospective analysis using German claims data","volume":"15","author":"Zhuleku","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"14","key":"10.1016\/j.dld.2023.04.022_bib0035","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.3390\/jcm11144202","article-title":"Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of Crohn's disease: systematic review and meta-analysis of observational studies","volume":"11","author":"Rub\u00edn de C\u00e9lix","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2023.04.022_bib0036","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2036.2002.01140.x","article-title":"The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review","volume":"16","author":"Loftus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.04.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006792.pub2","article-title":"Traditional corticosteroids for induction of remission in Crohn's disease","author":"Benchimol","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2023.04.022_bib0038","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.dld.2023.04.022_bib0039","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/MIB.0000000000000008","article-title":"Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease","volume":"20","author":"Targownik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.04.022_bib0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2023.04.022_bib0041","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2010.04489.x","article-title":"Review article: explaining risks of inflammatory bowel disease therapy to patients","volume":"33","author":"Siegel","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dld.2023.04.022_bib0042","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/MIB.0000000000001199","article-title":"Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel Disease","volume":"23","author":"Cohn","year":"2017","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823005820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823005820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:23:24Z","timestamp":1761625404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823005820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1590865823005820"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.04.022","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}